Edward Sturchio
Conseiller Juridique Général chez IMMATICS N.V.
Fortune : 1 M $ au 30/04/2024
Provenance du réseau au premier degré de Edward Sturchio
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 23 | |
| Subsidiary | Medical Specialties | 17 | |
| Public Company | Pharmaceuticals: Major | 3 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Edward Sturchio via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Pharmaceuticals: Major | Chairman Director/Board Member Chief Executive Officer Founder Director of Finance/CFO Director/Board Member Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Immatics US, Inc.
 Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Biotechnology | Chairman Director/Board Member Director/Board Member Chief Executive Officer Founder Director/Board Member Director/Board Member Founder Chief Tech/Sci/R&D Officer | |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
dievini Hopp BioTech holding GmbH & Co. KG
 dievini Hopp BioTech holding GmbH & Co. KG Investment ManagersFinance dievini Hopp BioTech holding GmbH & Co. KG operates as a private investment and consulting firm. It invests in companies related to the life and health sciences. It focuses with companies that diagnoses and provides therapy in the fields of oncology, neurology, infectious diseases, cell therapy and drug delivery systems. The company is headquartered in Walldorf, Germany. | Investment Managers | Private Equity Investor Founder Chief Executive Officer | |
| HEIDELBERG PHARMA AG | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
Molecular Health, Inc.
 Molecular Health, Inc. Packaged SoftwareTechnology Services Molecular Health, Inc. operates as a cloud-based healthcare decision support technology to enable evidence-based treatment decisions. The company was founded in 2004 and is headquartered in Boston, MA. | Packaged Software | Chairman Director/Board Member Director/Board Member | |
| AC IMMUNE SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Molecular Health GmbH
 Molecular Health GmbH Miscellaneous Commercial ServicesCommercial Services Part of Posbelduf Biotech AG, Molecular Health GmbH is a German management consulting company. The company is based in Heidelberg, Germany. The company was founded in 2004 by Friedrich von Bohlen und Halbach. Friedrich von Bohlen und Halbach has been the CEO since 2004. | Miscellaneous Commercial Services | Chief Executive Officer Chairman Director/Board Member | |
| Eberhard Karls Universität Tübingen | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
| dievini Verwaltungs GmbH | Chief Executive Officer Chief Executive Officer Chief Executive Officer | ||
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| Febit, Inc. | Director/Board Member Chairman | ||
| 2INVEST AG | Financial Conglomerates | Director/Board Member Director/Board Member | |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Director/Board Member Chairman | |
febit holding GmbH
 febit holding GmbH Medical/Nursing ServicesHealth Services febit holding GmbH engages in the design and development of technologies used for DNA analysis. It specializes in technologies with applications in genomic research, RNA expression profiling, and other diagnostic and molecular biology fields. The company was founded by Markus Beier, Ramon Gueimil, Peer F. Staehler, Matthias Scheffler, and Cord F. Stähler in 2005 and is headquartered in Heidelberg, Germany. | Medical/Nursing Services | Director/Board Member Chairman | |
| ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Novaliq GmbH
 Novaliq GmbH Medical SpecialtiesHealth Technology Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany. | Medical Specialties | Chairman Director/Board Member | |
Apogenix AG
 Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Biotechnology | Chairman Director/Board Member | |
| CUREVAC N.V. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Lantheus Medical Imaging, Inc.
 Lantheus Medical Imaging, Inc. Medical SpecialtiesHealth Technology Lantheus Medical Imaging, Inc. engages in the manufacture, marketing, sale, and distribution of medical imaging products. It provides diagnostic imaging and nuclear medicine products that assist clinicians with the detection of disease, primarily cardiovascular. Its product protfolio includes DEFINITY, TechneLite, Xenon, AZEDRA, Cardiolite, and NEUROLITE. The company was founded in 1956 and is headquartered in North Billerica, MA. | Medical Specialties | Director/Board Member Director/Board Member | |
| LANTHEUS HOLDINGS, INC. | Medical Specialties | Director/Board Member Director/Board Member | |
| PROGENICS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Advanced Accelerator Applications (UK & Ireland) Ltd.
 Advanced Accelerator Applications (UK & Ireland) Ltd. Medical SpecialtiesHealth Technology Imaging Equipment Ltd. distributes medical technologies. The firm offers PET and nuclear medical, imaging equipment, radiotherapy products, diagnostic imaging, radiation safety quality assurance, medical phantoms, ultrasound quality assurance products, molecular imaging, radiology tables, and bone densitometry products for the purpose of diagnosing osteoporosis. The company was founded in 2001 and is headquartered in Somerset, the United Kingdom. | Medical Specialties | Director/Board Member Director/Board Member | |
| University of Michigan | College/University | Undergraduate Degree Graduate Degree | |
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| IMMUNOCORE HOLDINGS PLC | Biotechnology | Chief Executive Officer Director/Board Member | |
| Rutgers State University of New Jersey | College/University | Undergraduate Degree Doctorate Degree | |
| Georgetown University | College/University | Undergraduate Degree Undergraduate Degree | |
| NPS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer General Counsel | |
| INFLARX N.V. | Biotechnology | Director of Finance/CFO Corporate Officer/Principal | |
| Bohlini GmbH & Co. KG | President | ||
| BLACK DIAMOND THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| EleGene AG | Director of Finance/CFO | ||
Replimune Ltd.
 Replimune Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Replimune Group, Inc., Replimune Ltd. is a British company that researches and develops cancer therapeutics. The company is based in Abingdon, UK and was founded in 2015. | Miscellaneous Commercial Services | Director/Board Member | |
| AVERY DENNISON CORPORATION | Containers/Packaging | Director of Finance/CFO | |
| LAVA THERAPEUTICS N.V. | Biotechnology | Chairman | |
| MEDIGENE AG | Biotechnology | Director of Finance/CFO | |
| AUTOLUS THERAPEUTICS PLC | Biotechnology | Director/Board Member | |
| Cf Port GmbH | Founder | ||
| VIVORYON THERAPEUTICS N.V. | Biotechnology | Director of Finance/CFO | |
Proteros biostructures GmbH
 Proteros biostructures GmbH Medical/Nursing ServicesHealth Services Proteros biostructures GmbH is a holding company which serves as a discovery service business. Its business areas are Discovery Pipeline, Discovery Services and Science & Technology. The Discovery Pipeline focuses on protein biochemistry, X-ray crystallography, biophysics, computational chemistry and property driven medicinal chemistry, Discovery Services offers drug discovery services with expertise and proprietary technologies for protein production, protein structure analysis, kinetic and thermodynamic profiling and Science & Technology segment focuses on industrialized structure-guided lead development infrastructure. The company was founded by Robert Huber and Torsten Neuefeind in 1999 and is headquartered in Martinsried, Germany. | Medical/Nursing Services | Director of Finance/CFO | |
| Avery Dennison GmbH | Director of Finance/CFO | ||
| REPLIMUNE GROUP, INC. | Biotechnology | Director/Board Member |
Statistiques
Internationale
| Allemagne | 27 |
| Etats-Unis | 17 |
| Royaume-Uni | 6 |
| Suisse | 2 |
| Belgique | 2 |
Sectorielle
| Health Technology | 30 |
| Commercial Services | 5 |
| Consumer Services | 5 |
| Finance | 3 |
| Health Services | 3 |
Opérationnelle
| Director/Board Member | 223 |
| Corporate Officer/Principal | 90 |
| Chairman | 76 |
| Independent Dir/Board Member | 66 |
| Chief Executive Officer | 55 |
Relations les plus connectées
| Insiders | |
|---|---|
| Christof Hettich | 40 |
| Kapil Dhingra | 39 |
| Claudio Costamagna | 38 |
| Friedrich von Bohlen und Halbach | 36 |
| Eliot Forster | 35 |
| Francois Nader | 28 |
| Peter Chambré | 23 |
| Mathias Hothum | 19 |
| Adam Stone | 17 |
| Michael Atieh | 16 |
| Carsten Reinhardt | 16 |
| Arnd Christ | 15 |
| Steven Gannon | 14 |
| Susanne Antonie Schaffert | 13 |
| Heather Mason | 13 |
- Bourse
- Insiders
- Edward Sturchio
- Connexions Sociétés
